17,786 Shares in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Acquired by J. Safra Sarasin Holding AG

J. Safra Sarasin Holding AG acquired a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 17,786 shares of the biopharmaceutical company's stock, valued at approximately $697,000.

Other institutional investors have also modified their holdings of the company. Geode Capital Management LLC raised its holdings in shares of Xenon Pharmaceuticals by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 69,529 shares of the biopharmaceutical company's stock worth $2,726,000 after purchasing an additional 720 shares during the period. KBC Group NV grew its position in shares of Xenon Pharmaceuticals by 39.8% during the fourth quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company's stock worth $107,000 after buying an additional 780 shares in the last quarter. HighMark Wealth Management LLC increased its stake in shares of Xenon Pharmaceuticals by 22.0% in the fourth quarter. HighMark Wealth Management LLC now owns 6,100 shares of the biopharmaceutical company's stock worth $239,000 after buying an additional 1,100 shares during the last quarter. Swiss National Bank raised its holdings in Xenon Pharmaceuticals by 1.0% in the fourth quarter. Swiss National Bank now owns 126,600 shares of the biopharmaceutical company's stock valued at $4,963,000 after acquiring an additional 1,300 shares in the last quarter. Finally, Blue Trust Inc. boosted its stake in Xenon Pharmaceuticals by 140.3% during the 4th quarter. Blue Trust Inc. now owns 2,422 shares of the biopharmaceutical company's stock valued at $95,000 after acquiring an additional 1,414 shares during the last quarter. Hedge funds and other institutional investors own 95.45% of the company's stock.

Analyst Ratings Changes

XENE has been the topic of several research reports. Deutsche Bank Aktiengesellschaft started coverage on Xenon Pharmaceuticals in a research note on Tuesday, February 11th. They set a "buy" rating and a $67.00 price objective on the stock. Royal Bank of Canada reissued an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. William Blair reaffirmed an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. StockNews.com upgraded shares of Xenon Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday. Finally, HC Wainwright restated a "buy" rating and issued a $53.00 target price on shares of Xenon Pharmaceuticals in a research note on Monday, February 24th. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $56.78.

Xenon Pharmaceuticals Stock Performance

Shares of XENE traded up $0.22 during mid-day trading on Monday, reaching $37.84. 502,056 shares of the company's stock traded hands, compared to its average volume of 571,916. The business's 50-day moving average price is $34.80 and its 200-day moving average price is $38.66. The stock has a market capitalization of $2.90 billion, a P/E ratio of -13.42 and a beta of 1.21. Xenon Pharmaceuticals Inc. has a 12 month low of $26.74 and a 12 month high of $46.00.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.05. Equities research analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.